Champions Oncolo Financials
This page shows Champions Oncolo (CSBR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Champions Oncolo has an operating margin of 8.0%, meaning the company retains $8 of operating profit per $100 of revenue. This results in a moderate score of 40/100, indicating healthy but not exceptional operating efficiency. This is up from -14.7% the prior year.
Champions Oncolo's revenue grew 13.5% year-over-year to $56.9M, a solid pace of expansion. This earns a growth score of 67/100.
Champions Oncolo has elevated debt relative to equity (D/E of 7.70), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.
Champions Oncolo's current ratio of 0.93 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 17/100, which could limit financial flexibility.
Champions Oncolo has a free cash flow margin of 12.3%, earning a moderate score of 61/100. The company generates positive cash flow after capital investments, but with room for improvement.
Champions Oncolo earns a strong 134.0% return on equity (ROE), meaning it generates $134 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100.
Champions Oncolo scores 0.40, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($80.7M) relative to total liabilities ($27.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Champions Oncolo passes 6 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Champions Oncolo generates $1.57 in operating cash flow ($7.4M OCF vs $4.7M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Champions Oncolo generated $56.9M in revenue in fiscal year 2025. This represents an increase of 13.5% from the prior year.
Champions Oncolo's EBITDA was $6.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 212.8% from the prior year.
Champions Oncolo generated $7.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 200.3% from the prior year.
Champions Oncolo reported $4.7M in net income in fiscal year 2025. This represents an increase of 164.6% from the prior year.
Champions Oncolo earned $0.33 per diluted share (EPS) in fiscal year 2025. This represents an increase of 161.1% from the prior year.
Champions Oncolo held $10.3M in cash against $0 in long-term debt as of fiscal year 2025.
Champions Oncolo had 14M shares outstanding in fiscal year 2025. This represents an increase of 1.3% from the prior year.
Champions Oncolo's gross margin was 50.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 8.8 percentage points from the prior year.
Champions Oncolo's operating margin was 8.0% in fiscal year 2025, reflecting core business profitability. This is up 22.7 percentage points from the prior year.
Champions Oncolo's net profit margin was 8.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 22.8 percentage points from the prior year.
Champions Oncolo's ROE was 134.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Champions Oncolo invested $6.8M in research and development in fiscal year 2025. This represents a decrease of 28.5% from the prior year.
Champions Oncolo spent $0 on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 100.0% from the prior year.
Champions Oncolo invested $389K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 53.5% from the prior year.
CSBR Income Statement
| Metric | Q2'25 | Q1'25 | Q3'25 | Q2'24 | Q1'24 | Q3'24 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15.0M+7.4% | $14.0M-17.9% | $17.0M+26.3% | $13.5M-4.1% | $14.1M+17.0% | $12.0M+3.9% | $11.6M-7.9% | $12.6M |
| Cost of Revenue | $7.3M-9.2% | $8.0M+20.8% | $6.6M-10.9% | $7.4M+5.0% | $7.1M-9.9% | $7.8M+18.6% | $6.6M-13.9% | $7.7M |
| Gross Profit | $7.8M+29.5% | $6.0M-42.4% | $10.4M+72.0% | $6.1M-13.3% | $7.0M+67.6% | $4.2M-15.8% | $5.0M+1.6% | $4.9M |
| R&D Expenses | $2.6M+25.6% | $2.1M+21.1% | $1.7M+1.8% | $1.7M+16.2% | $1.5M-33.5% | $2.2M-13.1% | $2.5M-10.0% | $2.8M |
| SG&A Expenses | $3.0M+15.7% | $2.6M+7.2% | $2.4M+26.9% | $1.9M-25.2% | $2.5M-8.6% | $2.8M+6.3% | $2.6M-11.6% | $2.9M |
| Operating Income | $185K+135.1% | -$527K-111.7% | $4.5M+514.6% | $732K-44.9% | $1.3M+151.6% | -$2.6M-31.8% | -$2.0M+23.4% | -$2.6M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $18K+28.6% | $14K-39.1% | $23K+109.1% | $11K-47.6% | $21K+90.9% | $11K0.0% | $11K-60.7% | $28K |
| Net Income | $268K+161.5% | -$436K-109.7% | $4.5M+517.4% | $728K-44.6% | $1.3M+151.9% | -$2.5M-22.2% | -$2.1M+19.3% | -$2.6M |
| EPS (Diluted) | $0.02+166.7% | $-0.03-109.7% | $0.31+520.0% | $0.05-44.4% | $0.09+147.4% | $-0.19-26.7% | $-0.15+21.1% | $-0.19 |
CSBR Balance Sheet
| Metric | Q2'25 | Q1'25 | Q3'25 | Q2'24 | Q1'24 | Q3'24 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $30.2M-1.3% | $30.5M-0.3% | $30.6M+21.3% | $25.2M+1.2% | $24.9M-6.9% | $26.8M-5.3% | $28.3M-5.4% | $29.9M |
| Current Assets | $21.3M+1.5% | $21.0M+6.7% | $19.7M+39.9% | $14.1M+6.9% | $13.2M-0.2% | $13.2M-5.8% | $14.0M-6.1% | $14.9M |
| Cash & Equivalents | $8.5M-17.5% | $10.3M+222.5% | $3.2M+16.3% | $2.8M-4.8% | $2.9M-35.3% | $4.5M-19.0% | $5.5M+13.2% | $4.9M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $11.5M+21.8% | $9.5M-40.0% | $15.8M+50.7% | $10.5M+15.9% | $9.0M+14.4% | $7.9M+2.5% | $7.7M-14.4% | $9.0M |
| Goodwill | $335K0.0% | $335K0.0% | $335K0.0% | $335K0.0% | $335K0.0% | $335K0.0% | $335K0.0% | $335K |
| Total Liabilities | $25.9M-4.0% | $27.0M+7.4% | $25.2M+2.4% | $24.6M-2.8% | $25.3M-12.4% | $28.8M+2.3% | $28.2M+0.7% | $28.0M |
| Current Liabilities | $22.1M-2.5% | $22.7M+14.2% | $19.9M+5.3% | $18.9M-1.6% | $19.2M-12.8% | $22.0M+4.9% | $20.9M+2.8% | $20.4M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $4.2M+18.9% | $3.5M-35.9% | $5.5M+703.1% | $681K+305.1% | -$332K+83.9% | -$2.1M-2312.9% | $93K-95.1% | $1.9M |
| Retained Earnings | -$80.1M+0.3% | -$80.4M-2.9% | -$78.1M+5.4% | -$82.6M+0.9% | -$83.3M+1.4% | -$84.5M-3.1% | -$82.0M-2.6% | -$79.9M |
CSBR Cash Flow Statement
| Metric | Q2'25 | Q1'25 | Q3'25 | Q2'24 | Q1'24 | Q3'24 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.7M-389.2% | $600K+22.4% | $490K+273.1% | -$283K-191.0% | $311K+133.8% | -$919K-256.0% | $589K+114.8% | -$4.0M |
| Capital Expenditures | $242K+426.1% | $46K+9.5% | $42K-55.3% | $94K | $0-100.0% | $92K+16.5% | $79K-88.2% | $668K |
| Free Cash Flow | -$2.0M-456.9% | $554K+23.7% | $448K+218.8% | -$377K-221.2% | $311K+130.8% | -$1.0M-298.2% | $510K+110.9% | -$4.7M |
| Investing Cash Flow | -$242K-426.1% | -$46K-9.5% | -$42K+55.3% | -$94K | $0+100.0% | -$92K-16.5% | -$79K+88.2% | -$668K |
| Financing Cash Flow | $168K+1300.0% | -$14K | $0-100.0% | $239K+745.9% | -$37K-8.8% | -$34K-125.4% | $134K+122.7% | -$590K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $0 | N/A | $0 | $0 | $0 | $0-100.0% | $32K-94.7% | $602K |
CSBR Financial Ratios
| Metric | Q2'25 | Q1'25 | Q3'25 | Q2'24 | Q1'24 | Q3'24 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 51.7%+8.8pp | 42.9%-18.3pp | 61.2%+16.2pp | 44.9%-4.8pp | 49.7%+15.0pp | 34.7%-8.1pp | 42.8%+4.0pp | 38.8% |
| Operating Margin | 1.2%+5.0pp | -3.8%-30.2pp | 26.4%+21.0pp | 5.4%-4.0pp | 9.4%+30.9pp | -21.4%-4.6pp | -16.9%+3.4pp | -20.3% |
| Net Margin | 1.8%+4.9pp | -3.1%-29.5pp | 26.4%+21.0pp | 5.4%-3.9pp | 9.3%+30.4pp | -21.1%-3.1pp | -17.9%+2.5pp | -20.4% |
| Return on Equity | 6.4% | N/A | 82.2%-24.7pp | 106.9% | N/A | N/A | N/A | N/A |
| Return on Assets | 0.9%+2.3pp | -1.4%-16.1pp | 14.7%+11.8pp | 2.9%-2.4pp | 5.3%+14.7pp | -9.4%-2.1pp | -7.3%+1.3pp | -8.6% |
| Current Ratio | 0.96+0.0 | 0.93-0.1 | 0.99+0.2 | 0.75+0.1 | 0.69+0.1 | 0.60-0.1 | 0.67-0.1 | 0.73 |
| Debt-to-Equity | 6.22-1.5 | 7.70+3.1 | 4.60-31.5 | 36.06+112.2 | -76.10-62.1 | -14.02-317.3 | 303.24+288.5 | 14.72 |
| FCF Margin | -13.2%-17.1pp | 4.0%+1.3pp | 2.6%+5.4pp | -2.8%-5.0pp | 2.2%+10.6pp | -8.4%-12.8pp | 4.4%+41.5pp | -37.1% |
Note: The current ratio is below 1.0 (0.93), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Champions Oncolo's annual revenue?
Champions Oncolo (CSBR) reported $56.9M in total revenue for fiscal year 2025. This represents a 13.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Champions Oncolo's revenue growing?
Champions Oncolo (CSBR) revenue grew by 13.5% year-over-year, from $50.2M to $56.9M in fiscal year 2025.
Is Champions Oncolo profitable?
Yes, Champions Oncolo (CSBR) reported a net income of $4.7M in fiscal year 2025, with a net profit margin of 8.3%.
What is Champions Oncolo's earnings per share (EPS)?
Champions Oncolo (CSBR) reported diluted earnings per share of $0.33 for fiscal year 2025. This represents a 161.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Champions Oncolo's EBITDA?
Champions Oncolo (CSBR) had EBITDA of $6.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Champions Oncolo's gross margin?
Champions Oncolo (CSBR) had a gross margin of 50.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Champions Oncolo's operating margin?
Champions Oncolo (CSBR) had an operating margin of 8.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Champions Oncolo's net profit margin?
Champions Oncolo (CSBR) had a net profit margin of 8.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Champions Oncolo's return on equity (ROE)?
Champions Oncolo (CSBR) has a return on equity of 134.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Champions Oncolo's free cash flow?
Champions Oncolo (CSBR) generated $7.0M in free cash flow during fiscal year 2025. This represents a 200.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Champions Oncolo's operating cash flow?
Champions Oncolo (CSBR) generated $7.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Champions Oncolo's total assets?
Champions Oncolo (CSBR) had $30.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Champions Oncolo's capital expenditures?
Champions Oncolo (CSBR) invested $389K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Champions Oncolo spend on research and development?
Champions Oncolo (CSBR) invested $6.8M in research and development during fiscal year 2025.
How many shares does Champions Oncolo have outstanding?
Champions Oncolo (CSBR) had 14M shares outstanding as of fiscal year 2025.
What is Champions Oncolo's current ratio?
Champions Oncolo (CSBR) had a current ratio of 0.93 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Champions Oncolo's debt-to-equity ratio?
Champions Oncolo (CSBR) had a debt-to-equity ratio of 7.70 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Champions Oncolo's return on assets (ROA)?
Champions Oncolo (CSBR) had a return on assets of 15.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Champions Oncolo's Altman Z-Score?
Champions Oncolo (CSBR) has an Altman Z-Score of 0.40, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Champions Oncolo's Piotroski F-Score?
Champions Oncolo (CSBR) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Champions Oncolo's earnings high quality?
Champions Oncolo (CSBR) has an earnings quality ratio of 1.57x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Champions Oncolo?
Champions Oncolo (CSBR) scores 48 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.